[HTML][HTML] Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Background Immune checkpoint inhibitors (ICI) have demonstrated impressive activity in
metastatic clear-cell renal cell carcinoma (ccRCC) and have become standard treatment …
metastatic clear-cell renal cell carcinoma (ccRCC) and have become standard treatment …
[HTML][HTML] Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
XQ Yan, MJ Ye, Q Zou, P Chen, ZS He, B Wu, DL He… - Annals of …, 2024 - Elsevier
Background Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are
standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III …
standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III …
Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC).
TPS4597 Background: Antiangiogenic agents, including sunitinib and axitinib, have shown
clinically significant efficacy in patients (pts) with mRCC. Results from a phase 1b study in 52 …
clinically significant efficacy in patients (pts) with mRCC. Results from a phase 1b study in 52 …
Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab
K Suzuki, T Terakawa, J Furukawa, K Harada… - International Journal of …, 2020 - Springer
Background Sequential treatment starting with target therapy is still the standard care for
metastatic renal cell carcinoma (mRCC), even in the era of immune checkpoint inhibitors …
metastatic renal cell carcinoma (mRCC), even in the era of immune checkpoint inhibitors …
New approaches to first-line treatment of advanced renal cell carcinoma
The treatment of patients with renal cell carcinoma (RCC) is evolving rapidly, with promising
new regimens being developed and approved for patients with advanced disease …
new regimens being developed and approved for patients with advanced disease …
Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies …
Longer follow-up and new trial data from phase 3 randomised controlled trials investigating
immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell …
immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell …
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell …
5008 Background: LEN, a multikinase VEGFR inhibitor, plus everolimus is approved for
advanced RCC after prior VEGF-targeted therapy. PEMBRO, an anti-PD-1 antibody, plus …
advanced RCC after prior VEGF-targeted therapy. PEMBRO, an anti-PD-1 antibody, plus …
A randomized phase II study of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in patients with advanced or metastatic clear-cell renal cell …
Purpose: MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and
durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may …
durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may …
Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study
S Demasure, I Spriet, PR Debruyne, A Laenen… - Acta …, 2022 - Taylor & Francis
Background Only a few recent phase III trials with targeted therapies or immune checkpoint
inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an …
inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an …
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label …
S Tamada, C Kondoh, N Matsubara, R Mizuno… - International Journal of …, 2022 - Springer
Background In the phase III open-label KEYNOTE-426 (NCT02853331) study, first-line
pembrolizumab and axitinib improved overall survival (OS) and progression-free survival …
pembrolizumab and axitinib improved overall survival (OS) and progression-free survival …